Toronto, Ontario–(Newsfile Corp. – April 17, 2024) – Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) (“Awakn” or the “Company”) a clinical-stage biotechnology company developing medication-assisted treatments for addiction with a near-term focus on Alcohol Use Disorder (AUD), is pleased to announce that, further to its press release dated April 3, 2024, it ..read more

Tel Aviv, Israel / Vancouver, Canada, April 17, 2024 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “company”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced an exclusive licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem. This partnership marks a significant step ..read more

Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced that its research manuscript, entitled “Synthesis and Structure-Activity Relationships of 2,5-dimethoxy-4-substituted phenethylamines and the discovery of CYB210010: A potent, orally bioavailable and long-acting serotonin 5-HT2 receptor agonist ..read more

TORONTO, April 18, 2024 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders, announced today that the U.S. Food & Drug Administration (“FDA”) has accepted ..read more

VANCOUVER, British Columbia, April 19, 2024 (GLOBE NEWSWIRE) — PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to announce that, further to its press release dated April 10 ..read more

The burgeoning interest in incorporating psychedelics into therapeutic practices has seen a marked rise over the past few years. Recent studies have revealed the potential benefits of substances like psilocybin, LSD, and ketamine in managing various mental health disorders. Therapists point out that psychedelics help dissolve the individual ego, an outcome sought in many spiritual ..read more

Alberta Blue Cross’s recent decision to include psychedelic-assisted therapy in their healthcare coverage marks a transformative moment in the perception and acceptance of psychedelic substances within mental health treatment paradigms. This groundbreaking initiative not only positions Alberta as the pioneering Canadian province to formalize insurance coverage for such treatments but also paves the way for ..read more

FSD Pharma Inc. (NASDAQ: HUGE)(CSE: HUGE) recently disclosed its audited financial results for the fourth quarter and the entirety of the fiscal year ending December 31, 2023. Currently, the company has not generated any revenue. For the year 2023, FSD Pharma reported a net loss of $18.2 million, which is an improvement from the previous ..read more

Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) has recently shared its financial achievements for both the final quarter and the entire fiscal year ending December 31, 2023. This period has been notable for the biotech firm specializing in the development of natural psychedelic drugs, as it reported promising increases in revenue and a ..read more

On April 16th, moderator David Rahn of Psy-Ins will sit with ketamine providers that have built or are currently building their ketamine companies.  During this conversation, the panelists will discuss the following topics: The group is bound to discuss many more topics overlapping with the topic so tune in to find out where the conversation ..read more